According to the company, CSL112 is a novel apolipoprotein A-I
infusion therapy that has been shown to have an immediate and significant impact on the ability to remove cholesterol from arteries.
The search terms used were "apolipoprotein A-I
," "ApoA-I," "apolipoprotein" combining with "tumor," "neoplasms," "malignancy," "carcinoma" OR "cancer." The search language was limited to English and Chinese.
Tetranectin and apolipoprotein A-I
in cerebrospinal fluid as potential biomarkers for Parkinson's disease.
mimetics and high-density lipoprotein function.
Interestingly, apolipoprotein A-I
, the structural protein of HDLs, was not identified as one of the proteins associated with HDL cholesterol.
Apolipoprotein B (apoB) represents the total number of apoB-containing lipoproteins  and is considered to be superior to LDL-C and non-HDL-C in predicting cardiovascular disease , whereas apolipoprotein A-I
(apoA-I) has a known inverse association and low levels are associated with increased body mass index (BMI) .
The overwhelming majority of HDL contains apolipoprotein A-I
Jungner, "Apolipoprotein B and apolipoprotein A-I
: risk indicators of coronary heart disease and targets for lipid-modifying therapy," Journal of Internal Medicine, vol.
The paradox of high apolipoprotein A-I
levels independently predicting incident type-2 diabetes among Turks.
Additionally, TB increased apolipoprotein A-I
concentrations and decreased apolipoprotein B concentrations.
Secondary measures included VLDL cholesterol, apolipoprotein A-I
, and apolipoprotein B.